ArticleJournal of clinical hypertension (Greenwich, Conn.)2020
Adrenal artery ablation for primary aldosteronism without apparent aldosteronoma: An efficacy and safety, proof-of-principle trial.
Article in Journal of clinical hypertension (Greenwich, Conn.), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Efficacy and Safety of Percutaneous Superselective Adrenal Arterial Embolization in the Treatment of Primary Aldosteronism With Bilateral Idiopathic Hyperaldosteronism: A Prospective Cohort Study
The Long-term Effect of Superselective Adrenal Arterial Embolization and Medical Treatment for Primary Aldosteronism on Cardiorenovascular Protection, Blood Pressure, and the Endocrinological Profile.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Clinical and Biochemical Outcomes of Super-Selective Adrenal Artery Embolization in Primary Aldosteronism: A Systematic Review and Meta-Analysis.Journal of clinical hypertension (Greenwich, Conn.) · 2025Pooled it
- The outcomes of transcatheter adrenal ablation in patients with primary aldosteronism: a systematic review and meta-analysis.BMC endocrine disorders · 2023Pooled it
- Bilateral superselective adrenal artery embolization for primary aldosteronism: A comparative evaluation of clinical efficacy and safety.The Journal of international medical research · 2026Observational
- Aldosterone and Impaired Nocturnal Blood Pressure Decline in Primary Aldosteronism.Journal of the American Heart Association · 2026Article
- The role of arachidonic acid metabolites in the subtype classification and pathogenesis of primary aldosteronism.iScience · 2026Article
- Beyond Drugs and Surgery: Superselective Adrenal Artery Embolization Redefines Primary Aldosteronism Management-A Systematic Review and Meta-Analysis.International journal of endocrinology · 2026Article
- The utility of 68Ga-pentixafor PET/CT in superselective adrenal artery embolization(SAAE) for treating aldosterone adenomas.European journal of nuclear medicine and molecular imaging · 2026Article
- Recent Advances in Adrenal Ablation for Primary Aldosteronism.American journal of hypertension · 2025Article
- Article
- Bilateral adrenal artery embolization for the treatment of idiopathic hyperaldosteronism: A proof-of-principle single center study.Hypertension research : official journal of the Japanese Society of Hypertension · 2025Article
- Clinical value of sublingual microcirculatory dysfunction for screening for primary aldosteronism in hypertensive patients.Frontiers in endocrinology · 2025Article
- Rationality and implication of catheter-based adrenal ablation for bilateral primary aldosteronism.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Safety and efficacy of bilateral superselective adrenal arterial embolization for treatment of idiopathic hyperaldosteronism: a prospective single-center study.BMC surgery · 2024Article
- Efficacy and safety of adrenal arterial embolization for primary aldosteronism: a systematic review and meta-analysis.Gland surgery · 2024Article
- The application of superselective adrenal artery embolization in primary aldosteronism: evaluation, challenges, and response to Mr. Cabrelle and his team.Hypertension research : official journal of the Japanese Society of Hypertension · 2024Article
- Treating Primary Aldosteronism-Induced Hypertension: Novel Approaches and Future Outlooks.Endocrine reviews · 2024Article
- Unilateral chemical ablation of the adrenal gland lowers blood pressure and alleviates target organ damage in spontaneously hypertensive rats.Hypertension research : official journal of the Japanese Society of Hypertension · 2023Article
- Primary Aldosteronism: State-of-the-Art Review.American journal of hypertension · 2022Article
- Clinical Characteristics of Target Organ Damage in Primary Aldosteronism with or without Metabolic Syndrome.Journal of diabetes research · 2022Article
- Therapeutic Outcomes with Surgical and Medical Management of Primary Aldosteronism.Current cardiology reports · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is associated with resistant hypertension and cardiovascular events. There are some limitations of current medical and surgical therapies for PA. To determine the efficacy and safety of catheter-based adrenal artery ablation for treatment of PA patients who refused both surgery and medical therapy, we performed this prospective cohort study. Thirty-six PA patients without apparent aldosteronoma were treated by adrenal artery ablation. Primary outcome was postoperative blood pressure and defined daily dose (DDD) of antihypertensive medications after adrenal ablation. Secondary outcome was biochemical success. We assessed outcomes based on Primary Aldosteronism Surgical Outcome (PASO) criteria. Adrenal CT scan, biochemical evaluation, adrenal artery ablation and adrenal venous sampling (AVS) were underwent. After adrenal ablation, complete clinical success (normotension without antihypertensive medication) was achieved in 9/36 (25.0%) patients and partial clinical success (reduction in blood pressure or less antihypertensive medication) in 13/36 (36.1%) patients. Complete biochemical success (correction of hypokalemia and normalization of aldosterone-to-renin ratio) was achieved in 16/36 (44.4%) patients. Office-based and ambulatory blood pressures were reduced by 17/7 and 11/2 mmHg at 6 months after ablation, respectively. The plasma cortisol level in the ablation group decreased slightly, but no patient developed hypoadrenocorticism. Catheter-based adrenal ablation appears to produce substantial and sustained blood pressure reduction and biochemical improvement, with only minor adverse events in PA patients without apparent aldosteronoma. This therapy could be an important supplement for current PA treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.